Pertuzumab patent expiry in vietnam?

I can help, but I need to clarify what you mean by “pertuzumab patent expiry” in Vietnam, because there are multiple “expiry” concepts:

1. Patent term expiry of the original product/compound patents filed in Vietnam (PCT/national phase), and/or
2. Supplementary protection (SPC/analogous extensions, if applicable), and/or
3. Registration/market exclusivity or local regulatory data protection (which is often different from patent expiry), and/or
4. Latest/secondary patents (formulations, manufacturing process, new dosing/regimens, combination use, etc.).

Quick reality check (high level)

• Pertuzumab (Perjeta®) is an older oncology biologic; in many jurisdictions the primary patent families and regulatory exclusivity have generally moved toward or past the middle/late 2010s into the 2020s, but Vietnam-specific dates depend on the exact local patent filings and whether any extensions were granted.
• Vietnam’s patent validity/expiry can’t be reliably inferred without checking the Vietnam IP database or specific patent numbers, because filings, grant dates, and claim scopes vary.

What I need from you to give an exact Vietnam expiry date

Please tell me one of the following:

• the Vietnam patent numbers (or WO/PCT numbers) you’re interested in, or
• the company/brand you mean (e.g., Roche/Genentech) and whether you mean product vs. process vs. formulation, or
• the link/source you’re working from (sometimes people have a specific patent list).

If you share any patent number(s) (even one), I can help you determine:

• the likely granted date,
• the term/expected expiry, and
• whether there are signs of adjustments/extensions that would affect the Vietnam date.

Which patent family are you referring to (or what are the patent numbers)?